Zobrazeno 1 - 10
of 17
pro vyhledávání: '"M, Bullejos Molina"'
Autor:
G Calzado Gómez, MA Navarro Davila, S Perez Reyes, C Romero Delgado, S Otazo Perez, Y Gonzalez Perez, M Bullejos Molina, GJ Nazco Casariego
Publikováno v:
Late breaking abstracts.
Autor:
M. Pérez Campos, J Nazco Casariego, N Yurrebaso Eguior, M Bullejos Molina, S. González Ponsjoan, C Romero Delgado, G Calzado Gómez, T. Virgós Aller
Publikováno v:
Eur J Hosp Pharm
Background The commercialisation of fixed-dose combination meant an improvement in antiretroviral therapy (ART). With generics we have the opportunity to maintain the therapy at a lower cost, but we complicate the dosage regimen again. Purpose To ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab780a626c1b55531c3381281534838
https://europepmc.org/articles/PMC7535606/
https://europepmc.org/articles/PMC7535606/
Autor:
M. J. Losada Castillo, L. M. Cordovés Dorta, E. Quijada Fumero, C. Mantolán Sarmiento, M Bullejos Molina, M. Serrano García, T. Virgós Aller, A. Pareja Ríos, V. Lozano López
Publikováno v:
Archivos de la Sociedad Española de Oftalmología. 90:14-21
Resumen Objetivo Analizar el beneficio coste-efectividad del implante intravitreo de dexametasona (Ozurdex ® , Allergan, Irvine, CA, EE. UU.) en sus aplicaciones clinicamente relevantes. Material y metodos Un total de 88 ojos de 86 pacientes con ede
Autor:
C. Mantolán Sarmiento, L. M. Cordovés Dorta, E. Quijada Fumero, M. J. Losada Castillo, T. Virgós Aller, A. Pareja Ríos, V. Lozano López, M Bullejos Molina, M. Serrano García
Publikováno v:
Archivos de la Sociedad Española de Oftalmología (English Edition). 90:14-21
Objective To analyse the cost-effectiveness and benefits of a dexamethasone intravitreal implant (Ozurdex®, Allergan, Irvine, CA, USA) in its clinically relevant applications. Materials and methods A total of 88 eyes of 86 patients with macular edem
Autor:
J Ramos Rodríguez, GA González de la Fuente, N Yurrebaso Eguilior, F Gutiérrez Nicolás, G Calzado Gómez, C Romero Delgado, GJ Nazco Casariego, M Bullejos Molina, S García Gil, MM Viña Romero
Publikováno v:
Clinical pharmacy.
Background Adalimumab is a subcutaneous anti-tumour necrosis factor antibody therapy used in the treatment of numerous pathologies related to rheumatology, dermatology and gastroenterology. This drug is on the top ranking of the annual hospital budge
Autor:
G Calzado Gómez, C Romero Delgado, F Gutiérrez Nicolás, T. Virgós Aller, GJ Nazco Casariego, M Bullejos Molina, I González Perera
Publikováno v:
Clinical pharmacy.
Background Immunity to malaria is complex, due to the replicative cycle of the parasite through intracellular and extracellular phases. Cellular and humoral immunity are necessary to contain the infection; it is more complicated in patients who regul
Autor:
J Nazco Casariego, G Calzado Gómez, M Suarez Gonzalez, M Bullejos Molina, N Roman Gonzalez, C Romero Delgado
Publikováno v:
Drug information and pharmacotherapy.
Background In recent years, new drugs have been approved for metastatic melanoma. The BRAF gene is the most common mutation in cutaneous melanomas and is present in 50% of melanomas. Vemurafenib and dabrafenib are used for the treatment of adult pati
Autor:
V, Lozano López, M, Serrano García, C, Mantolán Sarmiento, A, Pareja Ríos, M J, Losada Castillo, L, Cordovés Dorta, E, Quijada Fumero, T, Virgós Aller, M, Bullejos Molina
Publikováno v:
Archivos de la Sociedad Espanola de Oftalmologia. 90(1)
To analyze the cost-effectiveness and benefits of a dexamethasone intravitreal implant (Ozurdex®, Allergan, Irvine, CA, USA.) in its clinically relevant applications.A total of 88 eyes of 86 patients with macular edema of300 μm measured by optical
Autor:
I González Perera, J Nazco Casariego, M Suarez Gonzalez, J González García, G Calzado Gómez, M Bullejos Molina, C Romero Delgado
Publikováno v:
European Journal of Hospital Pharmacy. 23:A147.2-A148
Background Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits the mitochondrial enzyme dehidroorotato-dehydrogenase (DHO-DH), which is required for the synthesis of pyrimidine, blocking the proliferation of act
Autor:
J Nazco Casariego, G Calzado Gómez, C Romero Delgado, I Perera Gonzalez, J González García, M Bullejos Molina, M Suarez Delgado
Publikováno v:
European Journal of Hospital Pharmacy. 23:A144.1-A144
Background Multiple sclerosis (MS) is a chronic and inflammatory neurological disease in which focal demyelination occurs in the CNS. Dimethyl fumarate (DMF) is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis